{"id":"W4408980795","doi":"10.1016/s1556-0864(25)00395-8","title":"201P: Patient-reported outcomes (PROs) from the LAURA study: Osimertinib (osi) in patients with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) without progression after definitive chemoradiotherapy (CRT)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Osimertinib; Chemoradiotherapy; Oncology; Stage (stratigraphy); Internal medicine; Lung cancer; Radiology; Cancer; Epidermal growth factor receptor; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002203887,0.001058852,0.001103046,0.0005280516,0.0002522113,0.00135721,0.0006706349,0.0008559353,0.00386604],"category_scores_gemma":[0.002590176,0.0002339769,0.002944228,0.0009433954,0.000423076,0.00124523,0.001180847,0.001731046,0.0006624571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007035442,"about_ca_system_score_gemma":0.0004475741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00107918,"about_ca_topic_score_gemma":0.00323519,"domain_scores_codex":[0.9988407,0.0006120577,0.0000917919,0.0001700161,0.000156132,0.0001293015],"domain_scores_gemma":[0.9984702,0.0003643864,0.0007566638,0.00009511744,0.00009454261,0.0002190301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4270175,0.00179672,0.389408,0.003716504,0.0235095,0.0004606924,0.0002401658,0.006140782,0.004133288,0.001053753,0.02851379,0.1140093],"study_design_scores_gemma":[0.05974125,0.03030096,0.8632962,0.000713183,0.0197146,0.0008047759,0.0003088181,0.004878688,0.001886683,0.001568707,0.01657038,0.0002156852],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9537935,0.01064555,0.0006209189,0.001661621,0.0002519298,0.0004529904,0.02535914,0.0001052087,0.007109196],"genre_scores_gemma":[0.97003,0.001933222,0.0005493366,0.001294302,0.0002762939,0.0006944279,0.02293082,0.00003037379,0.002261238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00386604,"threshold_uncertainty_score":0.01293319,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01118334655084412,"score_gpt":0.3971920526254999,"score_spread":0.3860087060746558,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}